Table 3. Crude and weighted 3- and 5-year risk differences and risk ratios comparing postoperative oxaliplatin vs. postoperative 5-FU/capecitabine alone, patients age 66-74 years old.
| Outcome risk | |||||||
|---|---|---|---|---|---|---|---|
|
|
|||||||
| Outcome | Crude/Adjusted and time period | Postoperative 5-FU/capecitabine alone | Postoperative oxaliplatin | Risk difference | 95% CIa | Risk ratio | 95% CIa |
| All-cause mortality | Crude | ||||||
| 3-year | 0.12 | 0.15 | 0.03 | (-0.03, 0.10) | 1.28 | (0.76, 2.13) | |
| 5-year | 0.13 | 0.23 | 0.09 | (0.02, 0.17) | 1.71 | (1.03, 2.82) | |
| Weightedb | |||||||
| 3-year | 0.11 | 0.15 | 0.04 | (-0.03, 0.11) | 1.38 | (0.81, 2.36) | |
| 5-year | 0.12 | 0.23 | 0.10 | (0.03, 0.18) | 1.83 | (1.11, 3.03) | |
| Cancer-specific mortality | Crude | ||||||
| 3-year | 0.07 | 0.11 | 0.04 | (-0.03, 0.11) | 1.58 | (0.67, 3.69) | |
| 5-year | 0.11 | 0.15 | 0.04 | (-0.06, 0.13) | 1.34 | (0.57, 3.15) | |
| Weightedb | |||||||
| 3-year | 0.06 | 0.11 | 0.06 | (-0.02, 0.13) | 1.95 | (0.74, 5.15) | |
| 5-year | 0.09 | 0.15 | 0.05 | (-0.04, 0.15) | 1.59 | (0.62, 4.09) | |
Abbreviations: CI=confidence interval
a
Standard error based on standard deviation of 200 nonparametric bootstrap resamples.
b
Weighted for age (66-69, 70-74 years), sex, race/ethnicity, AJCC pathologic stage, married, metropolitan residence, census tract poverty level (%), COPD, diabetes, 30-day post-operative hospitalization, pre-operative therapy (chemoradiation or radiation therapy alone), predicted probability of ADL-D.